Guidant CE-marks Galileo system for long lesions:
This article was originally published in Clinica
Guidant has gained approval in Europe to expanded the market for its intravascular radiotherapy system for treating restenosis to include the treatment of longer coronary lesions. The Galileo system, first approved in Europe last year, has been CE-marked for sale as a treatment for long coronary lesions as long as 47mm.
You may also be interested in...
EU Regulatory Round-Up, February 2020: Brexit And Swixit Threaten Huge Disruption Amidst MDR Uncertainty
Complying with the EU’s new Medical Device Regulation would be hard enough. But more layers of uncertainty – especially Brexit and Swixit ̶ mean European medtech is navigating very turbulent waters right now.
Fresenius Kabi has reported sales ahead by 6% in 2019, as growth in emerging markets helped to offset a subdued increase in North America. Meanwhile, the firm has pushed back financial expectations for its biosimilars by a year.
Fresenius Kabi and Vifor Pharma have agreed to create a joint venture in China for intravenous iron products.